Overview

Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions

Status:
Not yet recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

A single center, open label, randomized, single-dose, two period, Two way cross-over study to explore the Bioequivalence of Test Product Xaroban (Rivaroxaban) 20 mg Tablet with the reference product Xarelto (Rivaroxaban) 20 mg tablet under fed conditions in healthy Pakistani male subjects. Subjects will receive one single dose per treatment period separated by a wash-out period of 7 days. Blood samples will be taken up to 48hours post-dose.

Phase:

Phase 1

Details

Lead Sponsor:

University of Karachi

Collaborator:

The Searle Company Limited Pakistan

Treatments:

Rivaroxaban